Infectious Diseases Overview

Summary

Introduction

A total of 11 companies make up the top five across each of the four ID sectors, their core competencies ranging from a single disease area to generics prowess, producing a comprehensive portfolio to providing a specific offerings corresponding to highest unmet need. This report characterises the key players in each sector, and their approach to maximising their returns from a pressurised sector.

Scope

• An inter and intra-sector overview of the four major components of the chemotherapeutic anti-infectives market in Japan, the US, and M5EU
• Disease backgrounds for each sector, drawing attention to the key clinical issues and unmet needs that shape commercial strategies for success
• Market size, structure, brand and company orientation by sector
• Portfolio analysis of the leading players by sector, highlighting winning tactics and strategies in portfolio management

Highlights

10 players in infectious disease account for two thirds of 7 major market chemotherapeutic anti-infective sales by value, but just one third by volume. However, as growth rates for the $38bn have fallen over the 2005-06 period, these companies have, collectively, been worst hit leading to a need for strategic re-evaluations for some players.

This has placed an increased emphasis on high value niches of the market, and the need for effective tactics to ensure revenue loss minimisation (including, for example, OTC leveraging), line extension (reformulation and own generic production) and product succession in different measures.

Other approaches have included minimising exposure to an anticipated continued shrinkage in the infectious disease market through scaling back infectious disease oriented operations altogether, focusing in on either areas considered to offer highest growth, or securing an exclusive grasp of a particular niche.

Reasons to Purchase

• Understand the clinical and commercial characteristics and priorities for the major anti-infectives markets across Japan, the US and M5EU
• Identify the elements of strategies that have either kept players at the top of their field or failed to facilitate growth
• Understand how these businesses and strategies relate to your interest in the market, and how to position your products and services accordingly

Contents

• Introduction
  • A Total Of 11 Companies Make Up The Top Five Across Each Of The Four Id Sectors, Their Core Competencies Ranging From A Single Disease Area To Generics Prowess, Producing A Comprehensive Portfolio To Providing A Specific Offerings Corresponding To Highest Unmet Need. This Report Characterises The Key Players In Each Sector, And Their Approach To Maximising Their Returns From A Pressurised Sector.
• Scope
  • An Inter And Intra-Sector Overview Of The Four Major Components Of The Chemotherapeutic Anti-Infectives Market In Japan, The Us, And M5eu Disease Backgrounds For Each Sector, Drawing Attention To The Key Clinical Issues And Unmet Needs That Shape Commercial Strategies For Success Market Size, Structure, Brand And Company Orientation By Sector Portfolio Analysis Of The Leading Players By Sector, Highlighting Winning Tactics And Strategies In Portfolio Management
• Highlights
  • 10 Players In Infectious Disease Account For Two Thirds Of 7 Major Market Chemotherapeutic Anti-Infective Sales By Value, But Just One Third By Volume. However, As Growth Rates For The $38bn Have Fallen Over The 2005-06 Period, These Companies Have, Collectively, Been Worst Hit Leading To A Need For Strategic Re-Evaluations For Some Players. This Has Placed An Increased Emphasis On High Value Niches Of The Market, And The Need For Effective Tactics To Ensure Revenue Loss Minimisation (Including, For Example, Otc Leveraging), Line Extension (Reformulation And Own Generic Production) And Product Succession In Different Measures. Other Approaches Have Included Minimising Exposure To An Anticipated Continued Shrinkage In The Infectious Disease Market Through Scaling Back Infectious Disease Oriented Operations Altogether, Focusing In On Either Areas Considered To Offer Highest Growth, Or Securing An Exclusive Grasp Of A Particular Niche.
  • Reasons To Purchase
  • Understand The Clinical And Commercial Characteristics And Priorities For The Major Anti-Infectives Markets Across Japan, The Us And M5eu Identify The Elements Of Strategies That Have Either Kept Players At The Top Of Their Field Or Failed To Facilitate Growth Understand How These Businesses And Strategies Relate To Your Interest In The Market, And How To Position Your Products And Services Accordingly.